Parenteral Manual

Nivolumab-Relatlimab (INVESTIGATIONAL)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Opdualag ® BMS-986213
Classification: 
Human IgG4 monoclonal anti-PD-1 and anti-LAG-3 antibody; immune checkpoint inhibitor. NON-CYTOTOXIC HAZARDOUS
Original Date: 
November 2026
Indications: 
  • INVESTIGATIONAL: treatment of relapsed and refractory solid tumours with high immune infiltration and/or replication repair deficiency in pediatric patients 12 years of age or older.
  • Health Canada approved for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma.
Reconstitution and Stability: 

Note: This is a combination product; each 1 mL of solution contains 12 mg of nivolumab and 4 mg of relatlimab. Dosing and administration are based off nivolumab component.

  • Supplied as 20 mL vials containing Nivolumab 240 mg (12 mg/mL) and Relatlimab 80 mg (4 mg/mL) solution for injection.
    • Vials are single-use and do not contain any preservative.
    • Vials must be refrigerated (2°C – 8°C) and protected from light. Do not freeze or shake vials.
    • Each vial is filled with 21.3 mL of solution, with 1.3 mL of overfill
  • May be infused undiluted (12 mg/mL of nivolumab) or diluted with 0.9% NaCl or D5W to a final concentration between 3 - 12 mg/mL of nivolumab (1 – 4 mg/mL relatlimab.
    • If diluted, the total infusion volume must not exceed 160 mL for patients =>40 kg; for patients <40 kg the total infusion volume must not exceed 4 mL/kg.
  • Avoid vigorous mixing or shaking during drug preparation and handling. Gently mix by manual rotation.
  • Administration of the infusion must be completed within 24 hours of preparation. If not used immediately, the infusion solution may be stored under refrigerated conditions for up to 24 hours, and a maximum of 4 hours of the total 24 hours can be at room temperature and room light.
    • The maximum 4-hour period under room temperature and room light conditions includes the administration period.
  • Inspect the nivolumab-relatlimab (Opdualag) solution for particulate matter or discolouration. Opdualag is a clear to opalescent, colourless to slightly yellow solution. Discard the vial if the solution is cloudy, discoloured, or contains extraneous particulate matter. Note: A few translucent-to-white particulates may be present (protein particulates)
Compatibility: 
  • Solutions compatible: 0.9% NaCl or D5W
  • Incompatible: do not administer other medications through the same IV line
Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Push NO
IV Intermittent Infusion

YES

Usual dilution: may be undiluted or diluted with 0.9% NaCl or D5W to a concentration between 3-12 mg/mL of nivolumab component (and 1-4 mg/mL of relatlimab). If diluted, do not exceed a total infusion volume of 160 mL for patients => 40 kg, or 4 mL/kg for patients <40 kg.

 

Infusion time: 60 minutes for first infusion. If tolerated without any infusion reactions, subsequent infusions may be given over 30 minutes.

 

Infuse with a sterile, non-pyrogenic, low protein binding 0.2 - 1.2-micron in-line filter After infusion, flush the IV line with NS or D5W.

IV Continuous Infusion NO

 

Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Dosing depends on indication and treatment protocol. Refer to specific protocol.

 

OPTIMISE trial (patients =>12 years of age and =>30 kg):

  • Fixed dose of Nivolumab 480 mg and Relatlimab 160 mg IV every 4 weeks
Potential hazards of parenteral administration: 
  • Infusion-Related Reactions: may include fever, chills, shakes, itching, rash, hyper/hypotension, difficulty breathing during and immediately after.
    • For any infusion toxicities, refer to protocol for detailed information on management.
    • Routine pre-medication is not required with nivolumab-relatlimab. Refer to protocol for pre-medication recommendations if history of an infusion reaction.
  • Common: fatigue, musculoskeletal pain, rash, pruritus, diarrhea, headache, nausea, vomiting, anorexia, weight loss, cough, dyspnea, hypothyroidism, abdominal pain
  • Immune-related reactions including rash, pneumonitis, colitis, hepatitis, pancreatitis, nephritis, endocrinopathies, myocarditis, meningoencephalitis, and neuropathies have been reported and may be severe or fatal. Onset may vary from days to many months and may occur after treatment has ended.
Notes: 
  • Anaphylactic precautions at bedside.
  • Patient should be monitored for 30 minutes after the end of the 1st infusion, with a repeat set of vital signs. If well tolerated, subsequent doses do not require observation after the infusion is complete.
  • Avoid systemic corticosteroids or immunosuppressants prior to starting nivolumab-relatlimab due to potential interference with its efficacy; refer to protocol for instructions on the use of corticosteroids or immunosuppressants in the management of immune-mediated adverse reactions
References: 
  • OPTIMISE Arm C Opdualag: Pharmacy Manual. Version 1.2, 27 Feb 2026.
  • Product Monograph: Opdualag™ (nivolumab and relatlimab for injection). Bristol-Myers Squibb Canada. Sep 2023.
  • Nivolumab/Relatlimab Drug Monograph. Ontario Health (Cancer Care Ontario). Nov 2024.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.